ELVN (Enliven Therapeutics) Total Equity : $288.40 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Enliven Therapeutics Total Equity?

Enliven Therapeutics's total equity for the quarter that ended in Sep. 2024 was $288.40 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Enliven Therapeutics Total Equity Historical Data

The historical data trend for Enliven Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enliven Therapeutics Total Equity Chart

Enliven Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Equity

-20.30

-42.89

-76.83

245.91

Enliven Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Equity	Get a 7-Day Free Trial									261.75	245.91	317.71	304.93	288.40

Enliven Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Enliven Therapeutics's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	271.867	-	25.961
	=	245.91

Enliven Therapeutics's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity	=	Total Assets(Q: Sep. 2024 )	-	Total Liabilities(Q: Sep. 2024 )
	=	305.43	-	17.027
	=	288.40

Enliven Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of Enliven Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Enliven Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enliven Therapeutics Inc (NAS:ELVN) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

6200 Lookout Road, Boulder, CO, USA, 80301

Website

https://www.enliventherapeutics.com

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Executives

Benjamin Hohl	officer: Chief Financial Officer	6200 LOOKOUT ROAD, BOULDER CO 80301
Samuel Kintz	director, officer: President and CEO	ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Helen Louise Collins	director	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Richard A. Heyman	director	5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121
Anish Patel	officer: Chief Operating Officer	C/O ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Joseph P Lyssikatos	director, officer: Chief Scientific Officer	6200 LOOKOUT ROAD, BOULDER CO 80301
Rahul D. Ballal	director, officer: President & CEO	116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Rishi Gupta	director, 10 percent owner	C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
5am Partners Vi, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jake Bauer	director	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Andrew J. Schwab	director	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p.	10 percent owner	501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107